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Abstract
Introduction Altered gut and pancreatic hormone secretion may bolster resolution of insulin resistance after Roux-en-Y gastric
bypass (RYGB), but the independent effects of weight loss and hormonal secretion on peripheral glucose disposal are unknown.
Methods Two groups of nondiabetic morbidly obese patients were studied: RYGB followed by standardized caloric
restriction (RYGB, n=12) or caloric restriction alone (diet, n=10). Metabolic evaluations (euglycemic–hyperinsulinemic
clamp, meal tolerance test) were done at baseline and 14 days (both groups) and 6 months after RYGB.
Results At baseline, body composition, fasting insulin, and glucose and peripheral glucose disposal did not differ between
groups. At 14 days, excess weight loss (EWL) was similar (RYGB, 12.7% vs. diet, 10.9%; p=0.12), fasting insulin and
glucose decreased to a similar extent, and RYGB subjects had altered postmeal patterns of gut and pancreatic hormone
secretion. However, peripheral glucose uptake (M value) was unchanged in both groups. Six months after RYGB, EWL was
49.7%. The changes in fasting glucose and insulin levels and gut hormone secretion persisted. M values improved
significantly, and changes in M values correlated with the % EWL (r=0.68, p=0.02).
Conclusions Improvement in peripheral glucose uptake following RYGB was observed only after substantial weight loss
had occurred and correlated with the magnitude of weight lost.
Keywords Bariatricsurgery.Insulinresistance.Obesity.
Morbidobesity.Gastricbypass.Weightloss.GLP-1.
Insulin.Type2diabetes.Diabetes.Calorierestriction.
Incretin
Introduction
Several bariatric surgical techniques originally designed
to promote weight loss offer a variable but impressive
rate of cure for type 2 diabetes mellitus (T2DM). In 80%
of patients who undergo Roux-en-Y gastric bypass
surgery (RYGB), T2DM resolves or improves signifi-
cantly.
1,2 RYGB is the most common bariatric surgical
technique used in the USA and seems to provide better
weight loss and higher rates of resolution of T2DM than
purely restrictive techniques such as laparoscopic gastric
banding.
3–5
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DOI 10.1007/s11605-009-1060-yThe proposed mechanisms to account for why RYGB
offers this remarkable rate of resolution of T2DM have
been under extensive scrutiny in both animals and
humans.
1,6–12 At the center of the debate is the relative
contribution of greater and sustained weight loss, or to an
altered pattern of gut and pancreatic hormone secretion,
frequently called the “incretin effect”, or other factors.
13,14
RYGB creates an anatomical rearrangement that delivers a
partially digested food bolus directly into the second
portion of the small bowel while avoiding contact with a
large portion of the stomach and the duodenum.
15–17 This,
in turn, results in altered glucose kinetics
18 and altered
secretion of many gut and pancreatic hormones known to
affect glucose metabolism
6,19 and has additional effects on
gastric emptying
20 and on neurohormonal gut–brain
signaling that regulates energy homeostasis and hunger–
satiety mechanisms.
10,20,21 However, to date, there have
been few detailed and controlled metabolic studies of the
interplay and independent effects of RYGB on the many
factors that affect insulin resistance and glucose metabo-
lism, such as beta cell function, the associated changes on
gut and pancreatic hormone levels, the magnitude and rate
of weight loss, energy balance, changes in body compo-
sition, and other factors. Information from such studies
might help clinicians and patients in choosing among
available surgical treatments for morbid obesity and guide
the search for novel surgical procedures to treat obesity-
associated T2DM in patients with lower body mass
indices (BMI). Therefore, the goal of this study was to
delineate short-term changes in total body glucose
disposal, gut and pancreatic hormone secretion, and body
composition, while controlling for energy balance and
delineate the same changes after more substantial weight
l o s sh a do c c u r r e d6m o n t h sa f t e rR Y G B .
Patients and Methods
Morbidly obese patients, selected to undergo gastric bypass
surgery(RYGB),wererecruitedattheUniversityofCalifornia,
San Francisco’s (UCSF) Bariatric Surgery Program. They met
the National Institute of Health and UCSF Bariatric Surgery
Program criteria for bariatric surgery: age 21 to 65 years old,
BMI either >40 or >35 kg/m
2 with high-risk comorbidities,
documented desire to undergo bariatric surgery, well in-
formed and motivated, acceptable operative risks, evaluated
and cleared for the procedure by a certified dietitian and a
psychiatrist or psychologist, documented repeated failure of
nonsurgical supervised weight loss programs, documented
BMI >35 kg/m
2 for more than 5 years, and ability and
willingness to provide informed consent. Exclusion criteria
included previous weight loss surgery; a previous esophageal,
gastric, pancreatic, adrenal, small bowel, large bowel, thyroid,
or central nervous system operation; diagnosis of thyroid,
liver, pancreatic, adrenal, hypothalamic, pituitary, ovarian,
and chronic renal disease; diagnosis of T2DM; use of insulin
or any oral medications for T2DM; or unwillingness or
inability to give informed consent. This project was approved
by the UCSF Committee of Human Research and the UCSF
Clinical and Translational Science Institute Clinical Research
Center (CRC) Advisory Committee.
Randomization and Metabolic Evaluation
Twenty-two patients were allocated to two groups: One
underwent immediate laparoscopic RYGB surgery followed
by standardized calorie restriction (RYGB, N=12), and the
other underwent caloric restriction only (diet, N=10).
Allocation to either group was determined by randomiza-
tion in the initial 17 patients studied and then by CRC and
surgery date availability in the last five patients.
All participants underwent the same baseline metabolic
evaluation (visit 1, V1). Subjects were admitted to the CRC
at 7:00 p.m. on study day 0 for an initial complete medical
history and physical examination. On that day, they began
an “ad libitum” diet up to a maximum intake of 25 kcal/kg/
24 h. Each morning upon arising, they were weighed on a
calibrated scale after voiding.
Meal Tolerance Test Onday1,participantsunderwentameal
tolerance test (MTT), which consisted of a standardized
300kcalin100mLliquidmealcontaining50% carbohydrate,
30% protein,and20% fat with9.9gofsimplesugarsina total
of 38 g carbohydrate, 10 g of fat, and 15 g of protein.
Participants were asked to consume this meal within a
maximum of 20 min. Blood samples, obtained through an
intravenous catheter inserted in the forearm, were drawn at
−120, −60, −5, 0, +5, +15, +30, +60 +120, and +180 min
relative to the start of the meal. After collection, the samples
were processed on site and stored at −70°C for subsequent
batch analysis of glucose, insulin, glucagon-like peptide-1
(GLP-1), and glucose-dependent insulinotropic polypeptide
(GIP; formerly known as gastric inhibitory polypeptide).
Euglycemic–Hyperinsulinemic Clamp On day 2, after an
overnight fast, peripheral glucose uptake was measured by
the hyperinsulinemic–euglycemic clamp method.
22 Insulin
(Humulin R, Eli Lilly, Indianapolis, IN, USA), bound to
albumin, was administered intravenously at a rate of
40 mU/m
2/min for 120 min. Blood was drawn by
intravenous catheter in a heated vein, and glucose concen-
trations were measured at 5-min intervals. Infusion of 20%
dextrose was adjusted to maintain a whole-blood glucose
level of 90 mg/dL. Peripheral glucose uptake (M value) was
calculated according to the method of DeFronzo et al.
22,
based on steady-state glucose infusion rates.
16 J Gastrointest Surg (2010) 14:15–23Body Composition Total body fat and lean body mass were
measured by dual-energy X-ray absorptiometry (Hologics
Discovery Wi, Bedford, MA, USA). Scanning was not
performed in subjects who weighed >350 lbs, the weight
limit for the scanner.
Surgery The participants assigned to immediate surgery
were discharged from the CRC and admitted for surgery the
next day. The RYGB was performed in a standardized
fashion by one author (GC); the technique has been
described in detail previously.
23,24 In brief, RYGB was
performed laparoscopically with six to seven ports. A 3.5-
mm linear stapler transected the stomach to create a 30-mL
gastric pouch. An antecolic gastrojejunostomy route was
always used. A circular gastrojejunal anastomosis with a
25-mm stapler was used. A biliopancreatic limb of 50 cm
and an alimentary limb of 100 cm were measured, and a
completely stapled side-to-side jejunojejunostomy was
created. Patients were discharged on postoperative day 2,
and none had perioperative complications.
Participants were then followed as outpatients for
14 days, during which they consumed a standardized low-
calorie diet: Optifast HP (Novartis Nutrition Corporation),
which provides 800 kcal/day (25% carbohydrate, 48%
protein, and 27% fat). Different flavors were available, and
participants were allowed to consume no-calorie, non-
carbonated soft drinks and water ad libitum. They were
given prepackaged servings and instructed to follow a
specific feeding schedule. Each participant had met with the
CRC dietitian during the baseline inpatient admission for
individualized instructions regarding the diet and counsel-
ing. During the 14-day outpatient period, participants were
asked to fill out daily logs of all food, water, and drinks
ingested and were contacted every other day by a research
fellow or coordinator from the Bariatric Surgery Clinic.
Adherence to the diet was assessed by alternate-day phone
calls from the research dietitian.
Follow-up in Patients Undergoing Diet Alone After com-
pleting the baseline evaluation and discharge from the CRC,
participants assigned to the diet group started the 14-day diet
period at home, following the identical diet routine as
described for the RYGB group above.
Follow-up Metabolic Assessments (Visit 2 and Visit 3) After
14 days, all participants were readmitted to the CRC and
underwent the same metabolic assessments performed at
baseline(visit2,V2).Theywerethendischargedandcontinued
their standard medical treatment. Six participants in the diet
group underwent RYGB after completing the V2 assessment.
A total of 12 subjects (nine originally assigned to RYGB and
three to diet who subsequently underwent RYGB) had a third
inpatient evaluation 6 months after RYGB (visit 3, V3).
Laboratory Analyses Whole-blood and plasma glucose
levels were measured by the glucose oxidase method (YSI
2300 STAT-Plus Glucose Analyzer, YSI Inc., Yellow
Springs, OH, USA). Serum insulin concentrations were
measured by radioimmunoassay (Millipore, St. Charles,
MO, USA). Active GLP-1 and GIP concentrations were
measured by enzyme-linked immunosorbent assay (Milli-
pore, St. Charles, MO, USA). The homeostasis model
assessment of insulin resistance (HOMA-IR) was calculated
as follows: fasting plasma glucose (millimoles per liter)×
fasting serum insulin (microunits per milliliter)/22.5.
25
Statistical Analysis
Data are summarized as mean and standard deviation unless
otherwise stated. The unadjusted association of proportions
and the distribution of continuous variables between groups
and the association of each variable with outcomes were
determined by two-sided t test and chi-square tests. Area
under the curve (AUC) was calculated using the trapezoidal
rule. Linear associations were measured using the Pearson’s
correlation coefficient. Statistical significance was consid-
ered to be p<0.05. SPSS, version 13.0.1 (SPSS Inc,
Chicago, IL, USA), was used for all statistical analyses.
Results
From October 2007 to January 2009, 59 patients met the
study criteria, 28 initially agreed to participate, and 22
completed the evaluation procedures. Twelve patients were
randomized or assigned to RYGB followed by standardized
caloric restriction (RYGB) and ten to caloric restriction
only (diet). The two groups did not differ with respect to
baseline demographics, body composition (Table 1), fasting
glucose and insulin, HOMA-IR, peripheral glucose disposal
(M value), or hormonal secretion during the MTT (Table 2).
Table 1 Demographic and Clinical Characteristics of the RYGB and
Diet Groups
RYGB
(n=12)
Diet only
(n=10)
p value
Female/Male 9:3 6:4 0.65
Age (years) 47.4±8.7 40.2±13.4 0.16
Weight (kg) 138.0±21.6 134.7±16.9 0.70
BMI (kg/m
2) 48.4±6.8 48.3±6.6 0.99
% Excess body weight 55.4±6.4 55.3±6.8 0.96
% Fat (by DEXA) 48.6±6.8 46.8±4.7 0.53
RYGB Roux-en-Y gastric bypass surgery, BMI body mass index,
DEXA dual-energy X-ray absorptiometry
J Gastrointest Surg (2010) 14:15–23 17At baseline, peripheral glucose uptake determined by the
euglycemic–hyperinsulinemic clamp was profoundly im-
paired in all subjects; average M value was about one third
of that for lean controls in our laboratory (2.1±0.9 vs. 7.6±
2.3 mg/kg/min, p<0.01).
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Metabolic Changes
After the 14-day diet period, the magnitude of weight loss
and changes in body composition did not differ between
groups. Fasting glucose, insulin, and HOMA-IR decreased
similarly in both groups (Table 2). M values did not change
in either group (RYGB (n=10), V1=2.4±0.9 vs. V2=2.3±
0.7 mg/kg/min, p=0.80 and diet (n=8), V1=1.8±1.0 vs.
V2=2.0±1.0 mg/kg/min, p=0.57; Fig. 1).
Insulin secretion over the 3-h postmeal period was
similar for V1 vs. V2 in both groups at baseline (Table 2),
but after RYGB, serum insulin levels in the first 30 min
after the meal were higher than for the diet group (RYGB,
V1=107±44 vs. V2=181±137 μU/mL; p=0.01 and diet,
V1=117±40 vs. V2=133±90 μU/mL, p=0.83; Fig. 2).
GLP-1 postmeal AUC increased significantly following
RYGB, whereas it did not change after diet only (Table 2).
GIP AUC increased after diet, whereas the values remained
low in the RYGB patients (Table 2). The increase in GLP-1
AUC in the RYGB group paralleled the early increase in
insulin release after RYGB (Fig. 2).
Metabolic Changes 6 Months After RYGB
Six participants in the diet group underwent RYGB after
completing V2 assessment. A total of 12 subjects under-
went a third inpatient evaluation 6 months after RYGB
(V3): nine subjects from the original RYGB group and
three from the diet group who underwent RYGB after
completing V1 and V2. Six months after RYGB, this group
of subjects had sustained significant weight loss (weight
loss=28.4±4.6 kg; EWL=49.7%, p<0.01 vs. V1) of which
74.5% was fat and had significant changes in fasting
glucose, insulin, and HOMA-IR compared to baseline
(Table 3). The magnitude of changes in fasting glucose,
insulin, and HOMA-IR observed at 6 months (V1–3) for
the patients originally assigned to RYGB was similar to
changes observed at 14 days (V1–2): change in glucose
V1–2=−7.8±2.9 vs. V1–3=−9.6±4.1 mg/dL, p=0.73;
change in insulin V1–2=−7.7±2.2 vs. V1–3=−12.6±
3.5 μIU/mL, p=0.25; and change in HOMA-IR V1–2=
−1.9±0.4 vs. V1–3=−3.0±0.7, p=0.25. The changes in the
postmeal serum levels and AUCs of GLP-1, GIP, and
insulin 6 months after RYGB remained similar to those
observed at 14 days (Tables 2 and 3). In contrast, peripheral
glucose uptake (M value) increased in all subjects at
6 months, reaching the upper boundary for the lowermost
quartile of values in healthy control subjects (Fig. 3).
Notably, the changes in M values correlated significantly
with the magnitude of weight lost (r=0.68, p=0.02; Fig. 4).
Discussion
Operations such as RYGB that bypass the duodenum and/or
stomach, thus allowing for early delivery of the food bolus
to the small intestine and preventing food bolus contact
with the duodenum, offer a unique opportunity for
identifying weight loss independent mechanisms for reso-
lution of diabetes.
9 Consequently, a variety of novel
surgical and endoscopic gastrointestinal procedures are
under investigation for use as therapeutic options in treating
T2DM.
27–31 Critical unanswered questions remain as to
whether or to what degree the altered patterns of gut and
pancreatic hormone secretion known to occur with bypass
operations bolster beta cell function and ultimately improve
peripheral glucose disposal and promote resolution of
T2DM independent of weight loss.
9 The fact remains,
however, that bariatric operations that result in greater
Table 2 Changes in Body Composition, and Baseline and Changes in
Fasting Glucose and Insulin, HOMA-IR, AUCs for Insulin, GLP-1,
and GIP During a Meal Tolerance Test at Baseline and 14 days
RYGB
(N=12)
Diet only
(N=10)
p
value
Weight loss (kg) 9.9±2.4 8.2±2.3 0.11
% Excess weight loss 12.7±2.4 10.9±2.8 0.12
% of weight lost as fat 40.4±16.2 29.9±16.8 0.22
Fasting glucose (mg/dL), baseline 94.8±12.0 99.6±14.7 0.41
Change in fasting glucose −7.8±10.1 −13.1±17.7 0.40
p value 0.02 0.04
Fasting insulin (μU/mL), baseline 22.4±14.4 34.1±20.1 0.15
Change in fasting insulin −7.7±7.5 −13.7±15.9 0.29
p value <0.01 0.02
HOMA-IR, baseline 5.1±2.9 8.9±7.0 0.14
Change in HOMA-IR −1.9±1.4 −4.6±6.2 0.22
p value 0.01 0.04
AUC insulin, baseline 196±70.6 276±89.3 0.03
Change in AUC insulin 33±131.6 −21±114.5 0.32
p value 0.40 0.57
AUC GLP-1, baseline 5.1±4.1 3.5±1.2 0.59
Change in GLP-1 AUC 13.4±11.0 0.5±1.6 <0.01
p value <0.01 0.24
AUC GIP, baseline 226.0±93.1 201.0±67.4 0.59
Change in GIP AUC −11.4±80.1 132.0±40.3 <0.01
p value 0.63 0.02
HOMA-IR homeostasis model assessment, AUC area under the curve,
MTT meal tolerance test
18 J Gastrointest Surg (2010) 14:15–23weight loss are still associated with greater rates of T2DM
improvement or cure.
1 In a recent systematic review and
meta-analysis, Buchwald and colleagues
1 showed that
excess weight loss and diabetes resolution in the first
12 months after surgery were the highest for patients
undergoing biliopancreatic diversion/duodenal switch
(BPD/DS; 64% excess weight loss, 95% diabetes resolu-
tion) followed by RYGB (60% excess weight loss, 80%
diabetes resolution) and the least for banding procedures
(46% excess weight loss, 57% diabetes resolution). How-
ever, BPD/DS and RYGB may impact and alter mecha-
nisms other than weight loss that play an independent role
in improving insulin resistance and allow for this high rate
of resolution of T2DM. The intricate interplay among
insulin sensitivity/resistance, glucose metabolism, and
insulin secretion is affected by many factors: beta cell
function; quality, distribution, and total fat mass; energy
balance and the magnitude of calorie restriction; hepatic
glucose and insulin metabolism and kinetics; quality and
quantity of nutrient intake and absorption; associated
diseases and stressors such as sleep apnea, liver fat, and
adipocytokines; and gut and pancreatic hormone secretion
and metabolism, among others.
9,32
In this study, we sought to delineate short-term changes
in peripheral glucose disposal, fasting measures of glucose
a n di n s u l i n ,g u ta n dp a n c r eatic hormone secretion in
response to a meal challenge, and body composition, while
controlling for energy balance, and to evaluate these same
changes after more substantial weight loss had occurred
6 months after RYGB. We confirmed previous studies in
showing that, after RYGB, the pattern of gut and pancreatic
hormone secretion following a meal is altered compared to
RYGB=  Roux-en-Y gastric bypass surgery
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Figure 2 Insulin and GLP-1 secretion after a meal, 14 days after RYGB
and calorie restriction or diet alone.
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Figure 1 Peripheral glucose uptake (M value) by euglycemic–hyperinsulinemic clamp before (baseline) and 14 days after either RYGB (a)o r
caloric restriction (b). The horizontal line indicates the upper boundary for the lower-most quartile of values seen in healthy control subjects.
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Table 3 Baseline Fasting Glucose, Insulin, HOMA-IR, AUCs for
Insulin, GLP-1, and GIP During a Meal Tolerance Test and Changes
6 Months After RYGB
RYGB (N=12
a)
Fasting glucose (mg/dL), baseline 91.9±10.3
Change in fasting glucose −9.6±14.2
p value 0.03
Fasting insulin (µU/mL), baseline 22.9±14.0
Change in fasting insulin −12.6±12.3
p value <0.01
HOMA-IR, baseline 5.1±2.8
Change in HOMA-IR −2.9±2.6
p value <0.01
AUC insulin, baseline 191±62
Change in AUC Insulin 2.1±103
p value 0.95
AUC GLP-1, baseline 3.7±2.2
Change in GLP-1 AUC 11.6±5.4
p value <0.01
AUC GIP, baseline 207.4±65.8
Change in GIP AUC −4.5±89.9
p value 0.87
HOMA-IR homeostasis model assessment, AUC area under the curve,
MTT meal tolerance test
aA total of 12 subjects underwent a third inpatient evaluation 6 months
after RYGB (visit 3): nine subjects from the original RYGB group and
three from the diet group who underwent RYGB after completing V1
and V2
J Gastrointest Surg (2010) 14:15–23 19controls
10,11,30,33 and that RYGB patients have early
improvements in fasting glucose, fasting insulin, and, thus,
in calculated HOMA-IR. Notably, the magnitude of
improvement in fasting glucose homeostasis was similar
in the group that underwent diet alone, indicating that
weight loss, rather than the surgical procedure, results in
these early changes. We also found that soon after RYGB
and before massive weight loss occurs, peripheral glucose
disposal (measured by euglycemic–hyperinsulinemic
clamp) was not improved. Taken together, these results
suggest that in the nondiabetic morbidly obese with severe
insulin resistance, the short-term effects of gastric bypass
surgery can improve glucose homeostasis under fasting
conditions before substantial weight loss occurs but are not
sufficient to improve peripheral glucose disposal during
hyperinsulinemia. Other investigators, using a variety of
techniques to study glucose metabolism, have documented
improvements in insulin resistance from 1 week to 1 month
after BPD/DS
34 and also RYGB with weight loss varying
from 9 to 15 kg.
34–37 In contrast to our study, these studies
were done in diabetic subjects and most were performed
without a diet-only control group. Nevertheless, these
differences support the notion that diabetic patients may
respond differently to these procedures than nondiabetics.
The altered pattern of gut hormone secretion may result
in amelioration of glucose disposal independently of weight
loss by many mechanisms. For example, GLP-1 reduces
elevated fasting and postprandial blood glucose levels in
diabetic humans; leads to glucose-dependent insulin secre-
tion, induction of beta-cell proliferation and expansion of
the beta-cell mass, and enhanced resistance to beta-cell
apoptosis; inhibits gastric emptying and acid secretion; and
reduces food ingestion and glucagon secretion, among
other functions.
20,38 We and others demonstrated that
RYGB is associated with an increased release of postpran-
dial GLP-1.
13,20,33,39 While the more rapid delivery of
glucose and other nutrients to the proximal intestine may
partially explain the rapid and robust insulin and GLP-1
responses following RYGB, the magnitude of the exagger-
ation of the GLP-1 response suggests that other unique
features with RYGB also contribute to this increase. In
another example, GIP, which is released from the duode-
num and proximal small bowel K-cells in response to
glucose and fat ingestion, augments glucose-stimulated
insulin secretion in healthy humans but almost completely
loses its insulinotropic effect in patients with T2DM.
20,33
Others have shown a blunted recovery of GIP levels in
obese diabetic patients, but not in obese nondiabetics, after
RYGB.
17,33,40 Patients in our current study, although not
classified as diabetics, had markedly impaired glucose
disposal, and the recovery of GIP secretion in diet-only
subjects after minimal weight loss and maintenance of low
levels of GIP in the RYGB group were similar to those
observed in diabetics in other studies.
17,33,40
A unique strength of our study was the use of the
hyperinsulinemic–euglycemic clamp and repeated testing
under controlled conditions. The clamp technique is widely
accepted as the reference standard for directly determining
insulin sensitivity and peripheral glucose disposal in
humans
41 and offers, in the research setting, significant
advantages over the commonly used technique for assess-
ing insulin sensitivity, such as HOMA-IR. The hyper-
insulinemic–euglycemic clamp leads to a steady-state
condition in which the glucose infusion rate during the
clamp must be equal to the glucose disposal rate. Thus, the
clamp estimates insulin sensitivity/resistance in humans and
directly measures peripheral glucose disposal at a given
level of insulinemia under steady-state conditions.
22,41 In
addition, the glucose clamp has excellent test character-
istics. Peripheral glucose uptake typically has a coefficient
Figure 4 Correlation in between changes in peripheral glucose
uptake (M values) and percent excess weight loss at 6 months after
RYGB (n=11).
Figure 3 Peripheral glucose uptake (M value) by euglycemic–
hyperinsulinemic clamp before and 6 months after RYGB (n=11).
20 J Gastrointest Surg (2010) 14:15–23of variation of 0.10 and a discriminant ratio of 6 (a
measurement of both reproducibility and the ability to
distinguish individual results).
42 On the other hand,
HOMA-IR, which has been used in many other studies of
the metabolic effects of bariatric surgery, is a simple
surrogate index for insulin resistance that is derived from
blood insulin and glucose concentrations under fasting
conditions and reflects mostly hepatic insulin sensitivity.
The main limitations of the glucose clamp approach are that
it is time-consuming, labor-intensive, expensive, and
requires an experienced operator to manage the technical
difficulties, but these were overcome by the use of CRC
resources and the experienced group of endocrinologists.
Moreover, because glucose and insulin are administered
parenterally during the clamp, thus bypassing the gut and
splanchnic metabolism, this technique measured peripheral
glucose uptake independent of any potential influence of
altered nutrient delivery to the small intestine or changes in
incretin secretion following RYGB.
Evidence from our study and others leaves little doubt that
calorie restriction alone can improve fasting glucose and
insulin levels and is an important factor leading to the rapid
changes observed after RYGB. However, as detailed above,
RYGB provides mechanisms that are independent of weight
loss and impact and/or bolster the ability of morbidly obese
patients to experience a more rapid amelioration of glucose
metabolism. However, fasting glucose and insulin measure-
ments, which are usually obtained as a surrogate for insulin
sensitivity in most studies performed to date and were the
measures that improved similarly at 14 days after RYGB or
calorie restriction only, are mostly a reflection of hepatic
insulin sensitivity. The M value obtained during the clamp
study provides the best estimate of peripheral glucose
homeostasis, and as we demonstrate, M values improved
only after significant weight loss and correlated with the
magnitude of weight loss.
Limitations of our study include small differences
between RYGB and diet groups in gender distribution,
weight loss, percentage of weight loss as fat, average daily
energy intake, and possible differences in diet absorption
that, although not statistically significant, when combined
may have impacted the results. Nevertheless, these differ-
ences in changes would have led to improvement in glucose
metabolism in the RYGB group. On the other hand, the
surgical insult and trauma of a laparoscopic operation for
RYGB may have had a negative impact, in the 14 day
analyses, on glucose homeostasis and disposal. Lastly, we
may have not been able to identify a differential and earlier
improvement in peripheral glucose disposal in the RYGB
group because we studied only nondiabetic participants and
studied them only at three time points. Although our
participants were profoundly insulin resistant, they may
have had effective counter-regulatory mechanisms that
successfully forestalled progression to diabetes, and thus,
we may have observed a different result had we studied
patients with diabetes.
With these limitations in view, we conclude that in
nondiabetic morbidly obese subjects under similar caloric
restriction and weight loss, peripheral glucose disposal is
not improved early after RYGB or calorie restriction.
Improvement in peripheral glucose disposal following
RYGB was observed only after substantial weight loss
had occurred and correlated with the magnitude of weight
lost. These findings suggest that weight loss is a critical
component for complete restoration of glucose homeostasis
in the morbidly obese with insulin resistance.
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Discussant
Dr. Bruce M. Wolfe (Portland, OR): Dr. Campos and
colleagues demonstrated that 2 weeks postgastric bypass,
GLP-1 and insulin secretion were enhanced, but peripheral
insulin resistance as reflected by glucose uptake did not
decrease until substantial weight loss occurred at 6 months
postoperatively. I have the following questions: First, you
indicated that all subjects demonstrated insulin resistance
prior to operations. Would you comment on the importance of
this finding?
Second, HOMA, a measure of insulin resistance calcu-
lated from fasting glucose and insulin decreased at 2 weeks,
but the clamp derived M score of glucose uptake and
22 J Gastrointest Surg (2010) 14:15–23peripheral insulin resistance did not. Is HOMA a useful
parameter in these studies or will further studies require the
extensive and burdensome clamp studies?
Finally, are you confident that the insulin infusion was
effective in shutting down hepatic gluconeogenesis allow-
ing you to draw conclusions regarding peripheral glucose
uptake?
Closing Discussant
Dr. Guilherme M. Campos (San Francisco, CA): Thank
you, Dr. Wolfe. Your questions highlight the need to clearly
understand the definition of diabetes and prediabetes and
that diabetes is a spectrum of a disease. What is interesting
in our patient population of morbidly obese individuals is
that none had a diagnosis of diabetes. All their fasting
glucose measures were below 105 and with normal
hemoglobin A1c, thus fitting the current criteria for
nondiabetics. However, when we studied and challenged
them using the hyperinsulinemic–euglycemic clamp, they
uniformly had peripheral insulin resistance and poor
peripheral glucose disposal. How to incorporate and apply
these tests in other studies? The clamp technique is widely
accepted as the reference standard for directly determining
insulin sensitivity and peripheral glucose disposal or uptake
in humans and offers, in the research setting, significant
advantages over the commonly used technique for assess-
ing insulin sensitivity, such as fasting measurements like
HOMA-IR. However, it cannot be used in large epidemi-
ological studies as it is indeed labor-intensive and expen-
sive. Thus, surrogate indices of insulin resistance, such as
HOMA-IR, are an acceptable alternative, but as shown in
our study, it will not identify all patients with impaired
glucose metabolism.
Lastly, was the amount of insulin chosen during the clamp
effective in suppressing hepatic gluconeogenesis?—the an-
swer is we do not know. We would have to have radiolabeled
glucose tracer studies to study hepatic glucose production to
see if the effect was indeed enough to suppress hepatic
gluconeogenesis. But that does not affect our results and
conclusions as we use the same amount of intravenous insulin
in all three evaluations using standard dosing per square
meter. So, even if hepatic gluconeogenesis was not sup-
pressed, the observed values and changes are still valid and
reliable.
Discussant
Dr. Nils Lambrecht (Los Angeles, CA): Do you have
any data on gastric sleeve surgery because the physical
removal of a large portion of the gastric oxyntic mucosa
including most ghrelin containing endocrine cells may play
a big role in changes in food intake and dietary behavior?
Closing Discussant
Dr.GuilhermeM.Campos(SanFrancisco,CA):No,wedo
not have data on gastric sleeve.
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